New potential therapeutic targets have been identified for diabetic kidney disease (DKD) – the leading cause of kidney failure in the world – that could see patients treated with new gene and drug therapies preventing the disease’s progression into end stage kidney failure.
Verve pauses lead base editing program after safety event, switches focus to follow-up candidate near clinic
Verve Therapeutics is pausing work on its lead gene editing treatment, which was the first time base editing was used to directly alter DNA in
April 3, 2024